# UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

> **NCT00039403** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage II Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** 7-hydroxystaurosporine
- **DRUG:** gemcitabine hydrochloride
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00039403
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2006-05
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039403, "UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00039403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*